Full Info:

Resource Type:

Webinar

Citation:

This third webinar in the IMPT’s “Let’s Talk MPTs” series provides MPT and HIV prevention product developers and other stakeholders with an overview of strategies to assess the toxicity of MPT drug candidates and describe the potential toxicity risks of pharmaceutical substances to the female reproductive tract.  Featured discussants were clinical infectious disease specialist Thomas Moench, MD, of Mapp Biopharmaceutical and Mucommune LLC, and Miles Brennan, PhD, a genetic engineering specialist currently focusing on monoclonal antibodies for infectious diseases at ZabBio, Inc.

Authors: The IMPT, Thomas Moench, Miles Brennan

Health Risks(s):

• HIV
• STI / STD
• Unintended Pregnancy

Product type(s):

• Antibodies
• MPTs

Topic(s):

• MPTs
• Development
• Trials
• Regulatory
• Reproductive Health
• Risk

Region(s)

• Global